FDAsafety guidance66% confidence
FDA AP — BKEMV (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Amgen; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application BLA761333. Sponsor: AMGEN INC. Submission status: AP. Submission type: SUPPL. Review priority: N/A. Active ingredients: ECULIZUMAB-AEEB.
Supporting Context
- Therapeutic area
- Hematology · Neutropenia
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for NEUPOGEN by Amgen